First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J. Morgan, J. Anthony Child, A. John Ashcroft et al.|The Lancet|2010Cited by 571
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyAndy C. Rawstron, Roger G. Owen, J. A. Child et al.|Journal of Clinical Oncology|2013Cited by 419
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Surita Dalal et al.|Blood|2025Cited by 2